Clinical data | |
---|---|
Trade names | Diamox, Diacarb, others |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration |
by mouth or intravenous |
ATC code | S01EC01 (WHO) |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 70–90% |
Metabolism | None |
Biological half-life | 2–4 hours |
Excretion | Urine (90%) |
Identifiers | |
|
|
CAS Number | 59-66-5 |
PubChem (CID) | 1986 |
IUPHAR/BPS | 6792 |
DrugBank | DB00819 |
ChemSpider | 1909 |
UNII | O3FX965V0I |
KEGG | D00218 |
ChEBI | CHEBI:27690 |
ChEMBL | CHEMBL20 |
PDB ligand ID | AZM (PDBe, RCSB PDB) |
ECHA InfoCard | 100.000.400 |
Chemical and physical data | |
Formula | C4H6N4O3S2 |
Molar mass | 222.245 g/mol |
3D model (Jmol) | Interactive image |
Melting point | 258 to 259 °C (496 to 498 °F) |
|
|
|
|
Acetazolamide, sold under the trade name Diamox among others, is a medication used to treat glaucoma, epilepsy, altitude sickness, periodic paralysis, and heart failure. It may be used long term for the treatment of open angle glaucoma and short term for acute angle closure glaucoma until surgery can be carried out. It is taken by mouth or injection into a vein.
Common side effects include numbness, ringing in the ears, loss of appetite, vomiting, and sleepiness. It is not recommended in those with significant kidney problems, liver problems, or who are allergic to sulfonamides. Acetazolamide is in the diuretic and carbonic anhydrase inhibitor families of medication. It works by decreasing the amount of hydrogen ions and bicarbonate in the body.
Acetazolamide came into medical use in 1952. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Acetazolamide is available as a generic medication. The wholesale cost in the developing world is about 1.40 to 16.93 USD per month. In the United States the wholesale cost is about 125.34 USD per month.